0%
The company’s founders defined the company through its name, ‘Akonni’ (of Native American origin). Akonni translates to “an attraction to the mysteries of nature, with a deep desire to understand those mysteries.”
Our mission is to develop, manufacture, and proliferate the adoption of game-changing molecular diagnostic tools for rapid, affordable and accurate of infectious diseases that will measurably improve the health status of millions of people worldwide.
The Akonni team envisions that our efforts and commitment will result in products which save lives and measurably improve the health status of millions of people worldwide.
We will innovate continuously and collaboratively to successfully address new disease diagnostic challenges.
Based on its recent analysis of the microarrays in molecular diagnostics (MDx) market, Frost & Sullivan recognizes Akonni Biosystems with the 2017 North American New Product Innovation Award.
Akonni’s integrated MDx system, TruDiagnosis®, is revolutionizing the point-of-care molecular testing market by enabling target detection from a variety of sample types. TruDiagnosis® is powered by TruArray®, a patented 3D gel-drop microarray technology for sample screening that instantly indicates the presence of disease markers in real time.
Download:
